Oncology and Hematology

33-48 of 162

• 

  RestartResume

  Data Dive: Clinical Evidence Behind CELMoDs

  RestartResume

  Data Dive: Clinical Evidence Behind CELMoDs

  MinuteCE®

  Data Dive: Clinical Evidence Behind CELMoDs

  1.00 program credit

  • 

    

    Sagar Lonial, MD, FACP

  1.00 program credit

• 

  RestartResume

  Mastering the Sequence: CELMoDs Across Treatment Lines

  RestartResume

  Mastering the Sequence: CELMoDs Across Treatment Lines

  MinuteCE®

  Mastering the Sequence: CELMoDs Across Treatment Lines

  1.00 program credit

  • 

    

    Sagar Lonial, MD, FACP

  • 

    

    Noopur Raje, MD

  1.00 program credit

• 

  RestartResume

  Safety First: Navigating CELMoD-Associated Toxicities

  RestartResume

  Safety First: Navigating CELMoD-Associated Toxicities

  MinuteCE®

  Safety First: Navigating CELMoD-Associated Toxicities

  1.00 program credit

  • 

    

    Joshua Richter, MD

  • 

    

    Noopur Raje, MD

  1.00 program credit

• 

  RestartResume

   Real-World Ready: Practical Tips for Community Oncologists

  RestartResume

   Real-World Ready: Practical Tips for Community Oncologists

  MinuteCE®

   Real-World Ready: Practical Tips for Community Oncologists

  1.00 program credit

  • 

    

    Joshua Richter, MD

  • 

    

    Sagar Lonial, MD, FACP

  1.00 program credit

• 

  RestartResume

  Case Application: Frontline Insights—Tackling Newly Diagnosed Myeloma

  RestartResume

  Case Application: Frontline Insights—Tackling Newly Diagnosed Myeloma

  MinuteCE®

  Case Application: Frontline Insights—Tackling Newly Diagnosed Myeloma

  1.00 program credit

  • 

    

    Joshua Richter, MD

  • 

    

    Noopur Raje, MD

  1.00 program credit

• 

  RestartResume

  Case Application: Unlocking Relapsed/Refractory Myeloma With CELMoDs

  RestartResume

  Case Application: Unlocking Relapsed/Refractory Myeloma With CELMoDs

  MinuteCE®

  Case Application: Unlocking Relapsed/Refractory Myeloma With CELMoDs

  1.00 program credit

  • 

    

    Joshua Richter, MD

  • 

    

    Sagar Lonial, MD, FACP

  1.00 program credit

• 

  RestartResume

  Next-Generation Innovations: The Future of CELMoDs in Myeloma

  RestartResume

  Next-Generation Innovations: The Future of CELMoDs in Myeloma

  MinuteCE®

  Next-Generation Innovations: The Future of CELMoDs in Myeloma

  1.00 program credit

  • 

    

    Noopur Raje, MD

  1.00 program credit

• 

  RestartResume

  Chairperson’s Perspective: Optimizing Perioperative Therapy in Early-Stage NSCLC: A Multidisciplinary Approach

  RestartResume

  Chairperson’s Perspective: Optimizing Perioperative Therapy in Early-Stage NSCLC: A Multidisciplinary Approach

  CME/CE

  Chairperson’s Perspective: Optimizing Perioperative Therapy in Early-Stage NSCLC: A Multidisciplinary Approach

  0.25 credits

  • 

    

    Heather Wakelee, MD, FASCO

  0.25 credits

• 

  MinuteCE®

  Innovations in Oncology Learning Center: From Guidelines to Practice: Melanoma

  1.00 credit 10 episodes

  • 

    

    John M. Kirkwood, MD

  • 

    

    Paolo A. Ascierto, MD

  • 

    

    Hussein Tawbi, MD, PhD

  • 

    

    Sapna Patel, MD

  1.00 credit 10 episodes

• 

  RestartResume

  Data Driving Recent Guideline Updates in Neoadjuvant Therapy for Resectable Melanoma

  RestartResume

  Data Driving Recent Guideline Updates in Neoadjuvant Therapy for Resectable Melanoma

  MinuteCE®

  Data Driving Recent Guideline Updates in Neoadjuvant Therapy for Resectable Melanoma

  1.00 program credit

  • 

    

    John M. Kirkwood, MD

  • 

    

    Sapna Patel, MD

  1.00 program credit

• 

  RestartResume

  Clinical Implications of Neoadjuvant Therapy Guideline Updates in Resectable Melanoma

  RestartResume

  Clinical Implications of Neoadjuvant Therapy Guideline Updates in Resectable Melanoma

  MinuteCE®

  Clinical Implications of Neoadjuvant Therapy Guideline Updates in Resectable Melanoma

  1.00 program credit

  • 

    

    John M. Kirkwood, MD

  • 

    

    Sapna Patel, MD

  1.00 program credit

• 

  RestartResume

  Efficacy and Safety Outcomes for Adjuvant Immunotherapy Driving Guideline Recommendations for Stage IIB/IIC Melanoma

  RestartResume

  Efficacy and Safety Outcomes for Adjuvant Immunotherapy Driving Guideline Recommendations for Stage IIB/IIC Melanoma

  MinuteCE®

  Efficacy and Safety Outcomes for Adjuvant Immunotherapy Driving Guideline Recommendations for Stage IIB/IIC Melanoma

  1.00 program credit

  • 

    

    Paolo A. Ascierto, MD

  1.00 program credit

• 

  RestartResume

  Efficacy and Safety Outcomes for Adjuvant Immunotherapy Driving Guideline Recommendations for Stage III/IV Melanoma

  RestartResume

  Efficacy and Safety Outcomes for Adjuvant Immunotherapy Driving Guideline Recommendations for Stage III/IV Melanoma

  MinuteCE®

  Efficacy and Safety Outcomes for Adjuvant Immunotherapy Driving Guideline Recommendations for Stage III/IV Melanoma

  1.00 program credit

  • 

    

    Paolo A. Ascierto, MD

  • 

    

    Hussein Tawbi, MD, PhD

  1.00 program credit

• 

  RestartResume

  Implementing Guideline-Concordant Care for a Patient With Newly Diagnosed Stage III Melanoma

  RestartResume

  Implementing Guideline-Concordant Care for a Patient With Newly Diagnosed Stage III Melanoma

  MinuteCE®

  Implementing Guideline-Concordant Care for a Patient With Newly Diagnosed Stage III Melanoma

  1.00 program credit

  • 

    

    Paolo A. Ascierto, MD

  • 

    

    Hussein Tawbi, MD, PhD

  1.00 program credit

• 

  RestartResume

  Data Driving Preferred Guideline Recommendations in First-Line Therapy for Metastatic Melanoma

  RestartResume

  Data Driving Preferred Guideline Recommendations in First-Line Therapy for Metastatic Melanoma

  MinuteCE®

  Data Driving Preferred Guideline Recommendations in First-Line Therapy for Metastatic Melanoma

  1.00 program credit

  • 

    

    Paolo A. Ascierto, MD

  • 

    

    Hussein Tawbi, MD, PhD

  1.00 program credit

• 

  RestartResume

  Implementing Guideline-Concordant Care for a Patient With Newly Diagnosed BRAF-Mutant Stage IV Melanoma

  RestartResume

  Implementing Guideline-Concordant Care for a Patient With Newly Diagnosed BRAF-Mutant Stage IV Melanoma

  MinuteCE®

  Implementing Guideline-Concordant Care for a Patient With Newly Diagnosed BRAF-Mutant Stage IV Melanoma

  1.00 program credit

  • 

    

    Hussein Tawbi, MD, PhD

  • 

    

    Sapna Patel, MD

  1.00 program credit

• Previous
• 1
• 2
• 3
• 4
• 5
• …
• 10
• 11
• Next